CCS
CLB icon

Crosspoint Capital Strategies’s Core Laboratories CLB Stock Holding History

Crosspoint Capital Strategies’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,511
Closed -$182K – 220
2015
Q4 		$182K Buy
1,511
+1,430
+1,765% +$164K 0.05% 247
2015
Q3 		$8K Buy
+81
New +$8.81K 0.01% 434
2014
Q2 		– Sell
-146
Closed -$29K – 527
2014
Q1 		$29K Buy
+146
New +$27.6K 0.01% 324

Other funds holding CLB

ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
WP
Wedgewood Partners St Louis, Missouri $484M AUM 14.59% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
SGA
Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Crosspoint Capital Strategies's CLB Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Core Laboratories (CLB) in Q1 2016, closing a stake of 1,511 shares — an estimated $182K sold.

Crosspoint Capital Strategies first reported a position in CLB in Q1 2014 and held it in 3 quarters. The position peaked at $182K in Q4 2015. 365 funds tracked by Wall St. Rank hold CLB as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining Core Laboratories position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 1,511 Core Laboratories shares in Q1 2016, an estimated $182K.
  • Crosspoint Capital Strategies first reported a position in Core Laboratories in Q1 2014 and held it in 3 quarters.
  • Crosspoint Capital Strategies's Core Laboratories position peaked at $182K in Q4 2015.
  • 365 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.